scholarly journals Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

2020 ◽  
Vol 33 (3) ◽  
pp. 201-207
Author(s):  
Grisuna Singh ◽  
Sejin Song ◽  
Eunjoo Choi ◽  
Pyung-Bok Lee ◽  
Francis Sahngun Nahm
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Zoster Vaccine ◽  
Recombinant Zoster Vaccine

scholarly journals Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure

2021 ◽  
Author(s):  
Hector S Izurieta ◽  
Xiyuan Wu ◽  
Richard Forshee ◽  
Yun Lu ◽  
Heng-Ming Sung ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Herpes Zoster ◽  
Real World ◽  
Postherpetic Neuralgia ◽  
Vaccine Effectiveness ◽  
Community Dwelling ◽  
Zoster Vaccine ◽  
Post Market ◽  
Recombinant Zoster Vaccine ◽  
Dose Vaccine

Abstract Background Shingrix™ (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed as two doses given 2–6 months apart, among adults ages ≥50 years. Clinical trials yielded efficacy of >90% for confirmed herpes zoster,but post-market vaccine performance has not been evaluated. Efficacy of a single dose, delayed second dose, or among persons with autoimmune or general immunosuppressive conditions have also not been studied. We aimed to assess post-market vaccine effectiveness of Shingrix. Methods We conducted a cohort study among vaccinated and unvaccinated Medicare Part D community dwelling beneficiaries ages >65 years. Herpes zoster was identified using a medical office visit diagnosis with treatment, and postherpetic neuralgia using a validated algorithm. We used inverse probability of treatment weighting to improve cohort balance, and marginal structural models to estimate hazard ratios. Results We found a vaccine effectiveness of 70.1% (95% CI, 68.6–71.5) and 56.9% (95% CI, 55.0–58.8) for two and one doses, respectively. The two-dose vaccine effectiveness was not significantly lower for beneficiaries 80+ years, for second doses received at ≥180 days, or for individuals with autoimmune conditions. The vaccine was also effective among individuals with immunosuppressive conditions. Two-dose vaccine effectiveness against postherpetic neuralgia was 76.0% (95% CI, 68.4-81.8). Conclusions This large real-world observational study of effectiveness of Shingrix demonstrates the benefit of completing the two-dose regimen. Second doses administered beyond the recommended 6 months did not impair vaccine effectiveness.Our effectiveness estimates were lower than the clinical trials estimates, likely due to differences in outcome specificity.

Is herpes zoster vaccine safe and effective for preventing zoster and postherpetic neuralgia?

2015 ◽  
Vol 18 (9) ◽  
pp. 9-10
Author(s):  
Emily Colson ◽  
Aaron TenHarmsel ◽  
Michael D. Geurin
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Zoster Vaccine

scholarly journals Human Vaccines and Herpes Zoster Ophthalmicus: Clinical Manifestation, Treatment, and Prevention

2020 ◽  
Vol 8 (F) ◽  
pp. 203-207
Author(s):  
Vina Yuwanda
Keyword(s):  
Herpes Zoster ◽  
Immunosuppressive Agents ◽  
Antibody Detection ◽  
Zoster Vaccine ◽  
Herpes Zoster Ophthalmicus ◽  
Varicella Zoster ◽  
Ocular Manifestations ◽  
Treatment And Prevention ◽  
Control And Prevention ◽  
Recombinant Zoster Vaccine

Herpes zoster ophthalmicus (HZO) is a reactivation of HZ virus that is latent in ophthalmic division of trigeminal ganglion. Patients over 50 years old, premature infant, pregnancy woman, receiving immunosuppressive agents, and malignancies are at risk of having HZO. Ocular manifestations of HZ are ectropion, entropion, ectopic eyelash, keratitis, conjunctivitis, symblepharon, hypoesthesia, episcleritis, scleritis, scleral atrophy and thinning, uveitis, iris atrophy, posterior synechiae, acute retinal necrosis, progressive outer retinal necrosis, retinal detachment, retina atrophy, optic neuritis, optic atrophy, and strabismus. Polymerase chain reaction, antigen detection, and antibody detection can help to confirm diagnosis. Pharmacology treatments for HZ ophthalmicus are antiviral drugs, corticosteroids, analgesics, tricyclic antidepressants, and antiepileptic drug. Non-pharmacology therapies are scleral contact lens, phototherapeutic keratectomy, photorefractive keratectomy, and penetrating keratoplasty. There are two kinds of vaccination which can be given to patients: Live-attenuated varicella zoster vaccine and recombinant zoster vaccine. It is recommended by Centers for Disease Control and Prevention and Food and Drugs Administration to use recombinant zoster vaccine by 50 years old.

Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster

2018 ◽  
Vol 22 (5) ◽  
pp. 417-422 ◽  
Author(s):  
Jacqueline R. Sly ◽  
Allyssa L. Harris
Keyword(s):  
Herpes Zoster ◽  
Zoster Vaccine ◽  
Recombinant Zoster Vaccine

scholarly journals The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine

2020 ◽  
Author(s):  
Alemnew F Dagnew ◽  
Nicola P Klein ◽  
Caroline Hervé ◽  
George Kalema ◽  
Emmanuel Di Paolo ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Herpes Zoster ◽  
T Cell ◽  
Immune Responses ◽  
Cd4 T Cell ◽  
Zoster Vaccine ◽  
Glycoprotein E ◽  
Cell Responses ◽  
Recombinant Zoster Vaccine ◽  
Over Time

Abstract Background Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients. Methods Adults aged ≥65 years who were previously vaccinated with ZVL ≥5 years earlier (n = 215) were group-matched with ZVL-naive individuals (n = 215) and vaccinated with RZV. Glycoprotein E (gE)–specific humoral and cell-mediated immune responses and the correlation between them, polyfunctional gE-specific CD4 T-cell responses, safety, and confirmed HZ cases were assessed. Results Through 12 months after dose 2, anti-gE antibody concentrations, gE-specific CD4 T-cell frequencies, and activation marker profiles were similar between groups. Safety outcomes were also similar. No HZ episodes were confirmed. Conclusions RZV induced strong humoral and polyfunctional cell-mediated immune responses that persisted above prevaccination levels through 1 year after dose 2 in adults aged ≥65 years irrespective of previous ZVL vaccination. The RZV safety profile was not affected. Clinical Trials Registration NCT02581410.

scholarly journals Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia: 2014 Update and consensus statement from the Canadian Pain Society

2015 ◽  
Vol 20 (1) ◽  
pp. 46-47 ◽  
Author(s):  
Canadian Pain Society Study Day participants
Keyword(s):  
Herpes Zoster ◽  
Pain Management ◽  
Advisory Committee ◽  
Postherpetic Neuralgia ◽  
Consensus Statement ◽  
Position Statement ◽  
Zoster Vaccine

The Canadian Pain Society (CPS) hosted its first Study Day in Toronto in July 2014, attended by experts in various fields of pain management and research (listed below). The aim was to review the National Advisory Committee on Immunization guidelines and to prepare a CPS position statement concerning the use of the zoster vaccine in Canada.

Sign in / Sign up

Export Citation Format

Share Document